Health Trials

Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:

ConditionsGliomas Harboring IDH1 and/or IDH2 MutationsGlioma Glioblastoma MultiformeGlioma of BrainstemGlioma, Diffuse Midline, H3K27M-mutantGlioma : Oligodendroglioma or AstrocytomaGliomas
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorXiangya Hospital of Central South University

About this trial

A vision-language model using preoperative MRI and clinical variables has been developed to simultaneously predict three key molecular markers in midline gliomas: H3K27M, IDH, and 1p/19q. This prospective multicenter study will validate the model's accuracy in preoperative molecular subtyping and its value in prognostic assessment and clinical decision-making across multiple neurosurgical centers.

Eligibility criteria

Qualifiers

Patients with diffuse gliomas were pathologically and molecularly diagnosed.

The clinical case data of all patients were complete.

Patients underwent preoperative MRI examination.

Disqualifiers

The tumor is not located in the intracranial midline.

Cases in which MRI were incomplete or with significant noise and artifacts.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Sponsors and collaborators

Xiangya Hospital of Central South University

Lead sponsor

Source ClinicalTrials.gov